Recommendations for follow-up of patients with cutaneous melanoma

Dermatologic Therapy

Volumn 10, Issue , 1999, Pages 83-87

  Kleeberg, Ulrich R ^b   Garbe, Claus ^b  

^a Hamatologisch Onkol Praxis Altona   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPIRATION BIOPSY; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER STAGING; DISEASE COURSE; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; MELANOMA; REVIEW; RISK FACTOR; TUMOR GROWTH;

EID: 0033045523     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Shumate CR, Urist MM, Maddox AM. Melanoma recurrence surveillance. Ann Surg 1995: 221: 566-571.
2. Weichenthal M, Altenhoff J, Kirchhoff A et al. Die Nachsorge bei Patienten mit malignem Melanom. Hamburger Ärzteblatt 1998: 1: 6-9.
3. Eggermont AMM. Nachbeobachtung von Patienten mit einem Melanom im Stadium I nach Excision des Primärtumors: einfach und kosteneffizient. Onkologe 1996: 2: 476-480.
4. Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol 1994: 20: 175-178.
5. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol 1993: 5: 174-180.
6. Kersey PA, Iscoe NA, Gapski JAP et al. The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 1985: 72: 614-617.
7. Regan MW, Reid CD, Griffiths RW, Briggs JC. Malignant melanoma, evaluation of clinical follow up by questionnaire survey. Br J Plastic Surg 1985: 38: 11-14.
8. Kleeberg UR, Schmoll HJ. Malignes Melanom. In: Schmoll HJ, Höffken K, Possinger K, ed. Kompendium Internistische Onkologie. Berlin: Springer Verlag, 1997: 1415-1460.
9. Henze G, Dummer R, Joller JH, Boni R, Burg G. Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatology 1997: 194: 208-212.
10. Schultz ES, Diepgen TL, Von-Den-Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998: 138: 426-430.
11. Koehler MR, Bosserhoff A, von-Beust G et al. Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics 1996: 35: 265-267.
12. Bosserhoff AK, Kaufmann M, Kaluza B et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997: 57: 3149-3153.
13. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998: 16: 1760-1769.
14. Farthmann B, Eberle J, Krasagakis K et al. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol 1998: 110: 263-267.
15. Blessing C, Feine U, Geiger L et al. Positron emission tomography and ultrasonography. Arch Dermatol 1995: 131: 1394-1398.
16. Prayer L, Winkelbauer H, Gritzmann N, Winkelbauer F, Helmer M, Pehamberger H. Sonography versus palpation in the detection of regional lymph-node metastases in patients with malignant melanoma. Eur J Cancer 1990: 26: 827-830.
17. Thompson JF, Saw RPM, Colman MH et al. Contralateral groin node metastasis from lower limb melanoma. Eur J Cancer 1997: 33: 976-977.
18. Kleeberg UR, Voigt H, Erdmann H. Die Zytodiagnostik von Melanommetastasen und ihre Bedeutung für die Wahl der Therapie. Tumor Diagn Ther 1984: 2: 49-54.
19. Kleeberg UR, Voigt H. Zytodiagnostik von Melanommetastasen. In: Voigt H, Kleeberg UR, ed. Malignes Melanom. Berlin: Springer Verlag, 1986: 111-117.
20. Kleeberg UR, Voigt H. Verlaufsdiagnostik und Nachsorge. In: Voigt H, Kleeberg UR, ed. Malignes Melanom. Berlin: Springer Verlag, 1986: 173-201.
21. Harpole DH, Johnson CM, Wolfe WG et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992: 103: 743-750.
22. Brand CU, Ellwanger U, Stroebel W et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997: 79: 2345-2353.
23. Garbe C. Increased survival in distant melanoma metastasis and the effect of treatments. Analysis of the disease course of patients with a survival of 2 years or more. Hautarzt 1996: 47: 35-43.
24. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 1993: 3: 291-299.
25. Kleeberg UR. Die Tumornachsorge bedarf der Neuorientierung! Heilkd Med 1995: 71: 687-691.
26. Kleeberg UR. Ergebnisqualität in der internistischen Onkologie: Aktueller Stand, Defizite und Zukunft. Onkologe 1998: 4: 414-419.
27. Kleeberg UR. Integration von Nachsorge und Rehabilitation. Status präsens, Defizite, Zukunft. Arzt Krankenhaus 1997: 69: 319-322.
28. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993: 91: 94-98.
29. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori 1994: 80: 188-197.
30. Frank W, Rogers GS. Melanoma update. Second primary melanoma. J Dermatol Surg Oncol 1993: 19: 427-430.
31. Cavegn B, Puppin D, Burg G. Kontroversen zum primären Melanom der Haut im Stadium I. Schweiz Med Wochenschr 1992: 122: 1883-1888.
32. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990: 212: 173-177.
33. Slingluff CL, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992: 70: 1917-1927.
34. Kleeberg UR. Wishful thinking, unicentric empiricism and the every day world of the medical melanomologist. Melanoma Res 1997: 7(suppl 2): 5143-5149.